Tests investigational drug CP-383 in adults with advanced solid tumors
Tests CP-383 in adults with advanced cancers such as lung and colorectal cancer.
Key facts
- Who runs it
- Tasca Therapeutics
- Where
- Cleveland, Dallas, Denver, Fairfax, Grand Rapids, Huntersville, Maumee, Omaha, Orlando, Philadelphia, San Antonio, St Louis, and West Valley City, United StatesSee the 13 sites
- Trial code
- Registry title
- Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 150 people, planned
- Started
- 27 Aug 2025
- Expected to end
- Feb 2029
- Type of study
- Interventional, 10 groups
- Treatments tested
- CP-383
- Record updated
- 18 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced or metastatic solid tumors that cannot be treated with standard therapy. Participants take CP-383 by mouth every day.
- Age
- 18 years and older
- Sex
- Men and women
- Disease stage
- Locally advanced, recurrent or metastatic cancer that cannot be cured. Part 1: any solid tumor except brain cancer, or colorectal, small cell lung, head and neck, non-small cell lung, pancreatic or bladder cancer. Part 2: colorectal, small cell lung or head and neck cancer, or selected solid tumors except brain cancer.
- Earlier treatment
- People must not be able to take standard cancer therapy, or it did not help, or it was too toxic. Certain anti-cancer or other drugs within a set time before the study drug are not allowed.
- Biomarker or test result
- Some cancers need a specific gene mutation in the tumor. A tumor sample must be available, or the person must be willing to have a biopsy.
Main reasons for not taking part
- Cannot swallow pills
- Active tumor in the brain
- Known HIV, HCV or HBV, unless controlled with an undetectable viral load
- Clinically significant liver, heart or gastrointestinal disease
- Pregnant or breastfeeding women
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Measurable or non measurable cancer that the research can assess for changes
- Not eligible or able to take existing standard therapies for cancer
- Availability of a part of a tumor for laboratory testing or willing to have a safe biopsy taken from a tumor
- Diagnosed with locally advanced, recurrent or metastatic incurable disease
- Part 1: any solid tumor (with the exception of brain cancer) that has progressed, standard therapy is no longer or has not helped the cancer, or is too toxic and for whom a clinical trial is an option for continued treatment
- Part 1: specific advanced, metastatic tumor types will also be enrolled: colorectal cancer, small cell lung cancer, head and neck cancer, non-small cell lung cancer, pancreatic cancer, bladder cancer - some of these will have a specific gene mutation in the cancer
- Part 1: selected solid tumor cancer types (with the exception of brain cancers) that have a specific gene mutation in the cancer
- Part 2: specific advanced, metastatic tumor types will also be enrolled: colorectal cancer, small cell lung cancer, head and neck cancer - some of these will have a specific gene mutation in the cancer; _ Part 2: selected solid tumor cancer types (with the exception of brain cancers) that have a specific gene mutation in the cancer
- Adequate blood and urine lab tests
- Women and men of childbearing potential with adequate contraception
- Provides written informed consent
- Willing to comply with the requirements of the protocol
Who cannot take part
- Known history of HIV, HCV, HBV unless cured, controlled with undetectable viral load
- Clinically significant liver disease
- Significant gastrointestinal diseases
- History of other cancer within past 5 years with certain exceptions for cancers that are likely cured
- Significant cardiac disease
- Other diseases that are not well controlled that could make taking the drug unsafe
- Exposure to certain anti-cancer or other drugs within a certain period before the start of study drug
- Inability to swallow pills
- Active tumor in the brain
- pregnant or lactating females
Where in United States
- Cleveland ClinicCleveland, United StatesContact: Taussig ResearchTaking people
- NEXT Oncology - DallasDallas, United StatesContact: Mofopefoluwa AkinwaleTaking people
- Sarah Cannon Research Institute at HealthONEDenver, United StatesContact: HealthOne DenverTaking people
- NEXT VirginiaFairfax, United StatesContact: Maybelle De La RosaTaking people
- START | MidwestGrand Rapids, United StatesContact: Colleen ArmstrongTaking people
- Carolina Biooncology InstituteHuntersville, United StatesContact: Hannah WallTaking people
- Taylor Cancer Research CenterMaumee, United StatesContact: Stephanie Ambrose, RN, BSN, CCRCTaking people
- Nebraska Cancer SpecialistsOmaha, United StatesContact: Ashley ServaisTaking people
- Florida Cancer Specialists - Lake NonaOrlando, United StatesContact: Elizabeth GilmoreTaking people
- University of PennsylvaniaPhiladelphia, United StatesContact: Roger Cohen, MDTaking people
- START | San AntonioSan Antonio, United StatesContact: Isabel JimenezTaking people
- Washington UniversitySt Louis, United StatesContact: Sara MitchumTaking people
- START Mountain RegionWest Valley City, United StatesContact: Marie AsayTaking people
About the trial
What the trial wants to find out
The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383. The main questions if aims to answer are:
Read full original descriptionShow less
* Does CP-383 slow or stop the growth of cancer in patients with advanced cancer * What medical problems do participants have when taking CP-383 Researchers will test CP-383 in all kinds of cancers at various dose levels to determine what the best dose is to study further. Researchers will also see if certain cancers that have gene mutations respond better to CP-383
Participants will:
* Take CP-383 every day by mouth until the researcher learns whether CP-383 is helping slow or reduce the cancer growth * Visit the clinic weekly for the first 6 weeks for checkups and tests * Visit the clinic every 3 weeks thereafter for checkups and tests
The 10 groups in the trial
- Dose Level 1Treatment being tested
CP-383, single daily oral capsule, 0.8 mg
Treatment: CP-383
- Dose Level 2Treatment being tested
CP-383, single daily oral capsule, 1.6 mg
Treatment: CP-383
- Dose Level 3Treatment being tested
CP-383, single daily oral capsule, 3.0 mg
Treatment: CP-383
- Dose Level 4Treatment being tested
CP-383, single daily oral capsule, 5.0 mg
Treatment: CP-383
- Dose Level 5Treatment being tested
CP-383, single daily oral capsule, 8.0 mg
Treatment: CP-383
- Dose Level 6Treatment being tested
CP-383, single daily oral capsule, 12 mg
Treatment: CP-383
- Expansion Arm 1Treatment being tested
Expansion in selected tumor type at recommended Phase 2 Dose of CP-383
Treatment: CP-383
- Expansion Arm 2Treatment being tested
Expansion in selected tumor type at recommended Phase 2 Dose of CP-383
Treatment: CP-383
- Expansion Arm 3Treatment being tested
Expansion in selected tumor type at recommended Phase 2 Dose of CP-383
Treatment: CP-383
- Expansion Arm 4Treatment being tested
Expansion in selected tumor type at recommended Phase 2 Dose of CP-383
Treatment: CP-383
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Multi-Center, Open Label, Phase 1/2 Study of CP-383, in Patients With Advanced or Metastatic Solid Tumors
- Plain-language title
- Tests investigational drug CP-383 in adults with advanced solid tumorsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 18 February 2026